The global pharmaceutical lipid-based excipients market size is anticipated to reach USD 2.42 billion by 2030 and is anticipated to expand at a CAGR of 4.8% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of poorly soluble drug candidates, representing 87% of pipeline candidates, has driven the adoption of advanced excipient solutions. Lipid-based excipients such as solid lipid nanoparticles and self-emulsifying drug delivery systems have become essential for complex molecules, addressing formulation challenges effectively. This surge reflects the pharmaceutical industry’s need for innovative solutions to enhance drug bioavailability and efficacy.
The integration of lipid-based excipients has revolutionized mRNA vaccines and gene therapies, as highlighted during the COVID-19 pandemic. Moreover, the demand for cost-effective excipients has further increased due to patent expirations for major pharmaceutical drugs. These factors underscore the transformative impact of lipid excipients on modern pharmaceutical development and their role in driving innovation in drug delivery.
Advancements in artificial intelligence (AI) and formulation technologies further contribute to the growth of the lipid excipients market. AI-driven modeling accelerates lipid based formulations, enhancing predictability and reducing time-to-market. Regulatory bodies maintain high expectations for lipid excipients, prioritizing patient safety by focusing on purity and safety characteristics, ultimately ensuring the quality and effectiveness of pharmaceutical products.
Request a free sample copy or view report summary: Pharmaceutical Lipid-Based Excipients Market Report
Based on excipients, oil excipients dominated the market in 2024, accounting for 40.5% of the total revenue due to advancements in lipid drug delivery, nutraceutical use, and demand for sustainable ingredients.
The lecithin and phospholipids segment is projected to grow at a robust CAGR over the forecast period.
Based on product applications, topical formulations led the market with the largest revenue share in 2024; however, ophthalmic applications are expected to grow at the fastest rate of 6.7% over the forecast period.
Based on disease, oncological applications of lipid-based excipients garnered the largest revenue in 2024, aided by a growing pipeline of targeted therapies and immunotherapies for cancer.
Based on industry, the nutraceutical (dietary supplements & others) segment is expected to witness the fastest CAGR over the forecast period, fueled by strategic partnerships between lipid excipient manufacturers and supplement-focused pharmaceutical companies.
As aging-related conditions become more widespread, the geriatric products (65+ years) segment is expected to witness the fastest CAGR of over 5.0% over the forecast period.
Based on end use, pharmaceutical manufacturers emerged as dominant end users in the market in 2024, accounting for 64.9% of the total revenue.
In April 2024, IOI Oleo GmbH launched DYNASAN CrystalCONTROL L for the cosmetics industry. This product addresses the “blooming” effect in stick formulations, improving product stability and aesthetics for a worry-free process globally.
Grand View Research has segmented the global pharmaceutical lipid-based excipients market on the basis of excipient type, product applications, disease application, industry application, age group, end-use, and region:
Pharmaceutical Lipid-based Excipients Type Outlook (Revenue, USD Million, 2018 - 2030)
Oils
Sesame Oil
Soybean Oil
Sunflower Oil
Linseed Oil / Flaxseed Oil
Safflower Oil
Coconut Oil
Arachis Oil / Peanut Oil
Corn Oil / Maize Oil
Olive Oil
Almond Oil
Castor Oil
Cotton Seed Oil
Grapeseed Oil
Other Oils
Hydrogenated Vegetable Oils
GMCC (Glyceryl Monostearate)
Hard Fats
Medium Chain Triglycerides (MCTs)
Lecithin and Phospholipids
Sodium Oleate
Capri Caprylic Mono Diglyceride
Others
Pharmaceutical Lipid-based Excipients Product Application Outlook (Revenue, USD Million, 2018 - 2030)
Oral Formulations
Softgel Capsules
Solid Dosage (Tablet, capsules, & pills)
Liquid Oral
Solid Lipid Nanoparticles (SLNs)
Parenteral
Small Volume Parenteral
Large Volume Parenteral
Topical Applications
Creams
Ointments
Others
Ophthalmic Applications
Eye Drops
Ocular Emulsions
Suppositories
Rectal Suppositories
Vaginal Suppositories
Other Suppositories
Others
Pharmaceutical Lipid-based Excipients Disease Application Outlook (Revenue, USD Million, 2018 - 2030)
Cardiovascular Diseases
Neurological Disorders
Oncology
Metabolic Disorders
Hormonal Therapies
Infectious Diseases
Pharmaceutical Lipid-based Excipients Industry Application Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical (OTC & Rx)
Nutraceutical (Dietary Supplements & Others)
Pharmaceutical Lipid-based Excipients Age Group Outlook (Revenue, USD Million, 2018 - 2030)
Pediatric Products (0-18 years)
Adult Products (19-64 years)
Geriatric Products (65+ years)
Pharmaceutical Lipid-based Excipients End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Manufacturers
Contract Development and Manufacturing Organizations (CDMOs)
Others
Pharmaceutical Lipid-based Excipients Region Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Thailand
South Korea
Australia
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Jordan
Egypt
Iran
Kuwait
List of Key Players in the Pharmaceutical Lipid-based Excipients Market
ABITEC Corporation
BASF
Gattefossé
CordenPharma
Lipoid
IOI Oleo GmbH
Croda International
Evonik Industries
Ashland
Merck KGaA
"The quality of research they have done for us has been excellent..."